RxDoctor Payments Data

Luis Rechani, MD

Clinical Cardiac Electrophysiology · Naples, FLNPI 1548226459

Payments from drug & device makers

$54,616in general payments, 2019–2025

Across 466 payments — averaging $117.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • Boston Scientific$16K
  • Medtronic$14K
  • Cardiva Medical, Inc.$993
  • Impulse Dynamics (USA) Inc.$804
  • Biosense Webster, Inc.$659
  • plus $3K from 25 others

What the payments were for

  • Speaking & faculty fees$12,60029%
  • Travel & lodging$4,92211%
  • Food & beverage$25,33559%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,616 in reported general payments places this provider in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$713,157
Medicare patients
1,217
Services billed
5,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$256,265
EntrestoSacubitril/Valsartan32$37,020
XareltoRivaroxaban37$33,618
Metoprolol Succinate217$2,989
Pindolol11$1,456
ClopidogrelClopidogrel Bisulfate60$1,073
Flecainide Acetate33$1,023
Sucralfate71$880
Propafenone Hcl ErPropafenone Hcl11$816
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$796
Nebivolol Hcl18$715
Pantoprazole Sodium84$496
SotalolSotalol Hcl27$492
Losartan Potassium38$409
Amiodarone Hcl31$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$256,265257 claims
Johnson & JohnsonXarelto$34$33,61837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →